| STARTSEITE |
 |
|
| Impressum |
| Datenschutz |
 |
 |
| SPOT ON | |
Hawthorn and Gingko biloba: protection of the status quo hampers adaptation to current knowledge | |
| THERAPY FROM A CRITICAL VIEWPOINT | |
Duration of antibiotic treatment for community-acquired pneumonia | |
| a-t READER'S QUESTIONS AND COMMENTS | |
Do proton pump inhibitors increase cardiovascular risk? | |
| IN BRIEF | |
Zoledronic acid (ZOMETA, generics) for bone metastases: is a longer treatment interval possible without loss in efficacy? | |
 |
Diethylstilbestrol (DES; in the past e.g. CYREN): harmful effects over three generations |
| CURRENT ADR NETWORK REPORT | |
Renal failure with levetiracetam (KEPPRA, generics) | |
| SIDE EFFECTS | |
Vasculitis and lichen planus with denosumab (PROLIA, XGEVA)? | |
|
© arznei-telegramm 1/2017 | ||
 | ||